Sutro Biopharma, INC Form 4 insider transactions

Sutro Biopharma Director Connie Matsui acquired 50,000 shares of common stock at $0.799 per share, signaling potential confidence in the company's future.

David Pauling, Chief Admin. Ofcr. & GC of Sutro Biopharma, acquired 12,504 shares of common stock, increasing his beneficial ownership.

Sutro Biopharma's Chief Scientific Officer, Hans-Peter Gerber, acquired 37,500 shares of common stock through RSU settlement and disposed of 13,417 shares for tax withholding.

Sutro Biopharma's Chief Business Officer, Barbara Leyman, reported the vesting of 25,000 restricted stock units and subsequent tax-related share withholding.

Sutro Biopharma's CEO, Jane Chung, filed a Form 4 detailing a future, pre-scheduled exercise of restricted stock units and net acquisition of common stock.

Sutro Biopharma, Inc. director Jon Marc Wigginton was granted 50,000 stock options with an exercise price of $0.85, vesting monthly over approximately one year.

Sutro Biopharma, Inc. (STRO) Director Daniel H. Petree has been granted 50,000 stock options with an exercise price of $0.85, aligning his interests with shareholders.

Sutro Biopharma, Inc. Director James P. Panek has acquired 50,000 stock options with an exercise price of $0.85, aligning his interests with long-term shareholder value.

Sutro Biopharma, Inc. director Connie Matsui was granted 50,000 stock options with an exercise price of $0.85 per share, vesting monthly from July 6, 2025.

Sutro Biopharma, Inc. Director Joseph M. Lobacki was granted 50,000 stock options with an exercise price of $0.85, vesting monthly and fully by June 2026.

Sutro Biopharma, Inc. Director Sukhi Jagpal was granted 50,000 stock options with an exercise price of $0.85, vesting over approximately one year.

Sutro Biopharma, Inc. Director Heidi Hunter was granted 50,000 stock options with an exercise price of $0.85, vesting monthly and fully by June 2026.

Sutro Biopharma, Inc. Director Michael Dybbs was granted 50,000 stock options with an exercise price of $0.85, vesting monthly and fully by June 2026.

Sutro Biopharma, Inc. (STRO) has granted its Chief Financial Officer, Gregory K. Chow, new equity compensation in the form of stock options and restricted stock units, aligning his long-term incentives with shareholder value.

Edward Albini, CFO and Secretary of Sutro Biopharma, reports changes in beneficial ownership due to the accelerated vesting of restricted stock units (RSUs) in connection with his separation from the company.

Linda Fitzpatrick, Chief People & Communications Officer of Sutro Biopharma, reports changes in her beneficial ownership of company stock and restricted stock units (RSUs) due to accelerated vesting upon her separation from the company.

Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, reports the acquisition and disposal of common stock and restricted stock units on May 1, 2025.

Anne Elizabeth Borgman, Chief Medical Officer of Sutro Biopharma, reports changes in beneficial ownership of common stock and restricted stock units (RSUs) due to vesting and tax withholding related to her separation from the company.

Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

CEO Jane Chung reports the acquisition of stock options and restricted stock units (RSUs) in Sutro Biopharma, Inc.

Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Barbara Leyman, Chief Business Development Officer of Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs) on April 4, 2025.

Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, received stock options and restricted stock units (RSUs) on April 4, 2025.

David Pauling, Chief Administrative Officer & General Counsel of Sutro Biopharma, acquired stock options and restricted stock units (RSUs) according to a Form 4 filing.

William Newell, CEO of Sutro Biopharma, reports the vesting and tax withholding of restricted stock units.

Linda Fitzpatrick, Chief People & Communications Officer at Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

CFO and Secretary of Sutro Biopharma, Edward Albini, reports the vesting of restricted stock units and subsequent tax withholding.

CFO Edward Albini reports the vesting and tax withholding of Sutro Biopharma stock.

Linda Fitzpatrick, Chief People & Communications Officer at Sutro Biopharma, reports the vesting and tax withholding of restricted stock units.

William J. Newell, CEO of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.